--- title: "ZAWYA: Sidra Medicine advanced Imaging Core recognized as ZEISS labs@location Reference Customer" type: "News" locale: "en" url: "https://longbridge.com/en/news/286269565.md" description: "Sidra Medicine in Qatar has been designated as a ZEISS labs@location Reference Customer through its Advanced Imaging Core (AIC). This recognition places Sidra among a select group of international research hospitals and academic centers known for excellence in advanced microscopy and imaging technologies. The designation enhances Sidra's ability to support researchers and clinicians, strengthens its competitiveness for grants, and reinforces its position as a regional hub for precision medicine and scientific collaboration." datetime: "2026-05-13T13:20:48.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286269565.md) - [en](https://longbridge.com/en/news/286269565.md) - [zh-HK](https://longbridge.com/zh-HK/news/286269565.md) --- # ZAWYA: Sidra Medicine advanced Imaging Core recognized as ZEISS labs@location Reference Customer **Doha, Qatar –** Sidra Medicine, a member of Qatar Foundation, has been formally designated as a ZEISS labs@location Reference Customer through its Advanced Imaging Core (AIC). The designation places Sidra Medicine among a select international network of research hospitals, academic medical centers, and core facilities recognized for excellence in advanced microscopy and imaging technologies. The ZEISS labs@location Program is designed to strengthen collaboration between ZEISS and leading laboratories worldwide by supporting the development of imaging applications, scientific training, expert demonstrations, and knowledge exchange. Dr. Abbirami Sathappan, Lead, Advanced Imaging Core at Sidra Medicine said: “Being recognized as a ZEISS labs@location Reference Customer reflects the strength of the expertise, infrastructure, and collaborative environment we have built within the Advanced Imaging Core. The designation strengthens our ability to support researchers and clinicians with advanced imaging workflows that accelerate discovery and contribute to clinically relevant research.” The designation was awarded following an evaluation of Sidra Medicine’s Advanced Imaging Core, which demonstrated advanced imaging capabilities, strong operational standards, scientific expertise, and the ability to provide high-level training and knowledge transfer. The center was also recognized for its ability to support complex imaging applications, publication-grade research, and collaborative scientific initiatives. Through the designation, Sidra Medicine joins an elite group of institutions selected based on scientific excellence and innovation, placing the organization alongside globally recognized leaders in imaging science and biomedical research. Prof. Khalid Fakhro, Chief Research Officer at Sidra Medicine said: “We are very proud today of this exceptional recognition of our Advanced Imaging Core. At Sidra Medicine, our philosophy has always been to invest in developing state-of-the-art core research platforms, led by visionary staff building testing capabilities with direct relevance for patient care. This designation by Zeiss underscores our mission to advance diagnostics and mechanistic understanding of rare and complex diseases, which ultimately translates to more precise treatment and improved outcomes for patients." Dr. Sara Tomei, Director of Integrated Genomic Services at Sidra Medicine said: “The recognition strengthens Sidra Medicine’s competitiveness for peer-reviewed grants and international research collaborations by demonstrating institutional capability, technology leadership, and training excellence. It also supports the development of local expertise through structured training opportunities for clinicians, fellows, researchers, and technologists.” The ZEISS labs@location designation supports Sidra Medicine’s broader mission to integrate advanced technologies into research and clinical innovation, further advancing precision medicine and improving outcomes for patients and families in Qatar and beyond. It also reinforces Sidra Medicine’s position as a regional hub for precision medicine, translational research, and multidisciplinary scientific collaboration. **About Sidra Medicine** Innovating Care. Transforming Lives From the heart of Qatar, Sidra Medicine, is a private, not-for-profit academic healthcare and research institution for women, children, and young people. Established by the Qatar Foundation for Education, Science, and Community Development, Sidra Medicine is committed to delivering exceptional patient and family-focused care, conducting innovative biomedical and clinical research, and providing a personalized journey of care and cure and precision medicine specifically for rare and genetic diseases. To access our specialized healthcare and international patient services, including pediatric care, women's health, and rare disease treatment or to book a consultation at one of our private clinics, please call +974 40033333, visit our website at http://www.sidra.org,or download the Sidra Medicine app, available on the App Store and Google Play. For more information, follow us on Facebook, Instagram, X, TikTok, Snapchat and LinkedIn. Send us your press releases to pressrelease.zawya@lseg.com Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release. The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk. To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages. ### Related Stocks - [AFX.DE](https://longbridge.com/en/quote/AFX.DE.md) ## Related News & Research - [Carl Zeiss Meditec (0DHC) Gets a Sell from J.P. Morgan](https://longbridge.com/en/news/286208300.md) - [ZAWYA: WCM-Q launches expanded LifeHub project in Msheireb Downtown](https://longbridge.com/en/news/286888323.md) - [ZAWYA: QIB named Best Retail Bank in Qatar by The Asian Banker](https://longbridge.com/en/news/287047847.md) - [ZAWYA: Qatar Tourism launches service excellence training for MoI immigration officers in collaboration with HIA](https://longbridge.com/en/news/286757769.md) - [ZAWYA: QFC joins GCMA to advance Qatar’s asset management ecosystem](https://longbridge.com/en/news/286712591.md)